EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Increased ATP production and P‐glycoprotein activity underlie the marked changes in blood–brain barrier transport of drugs in a mouse model of amyotrophic lateral sclerosis

Yijun Pan iD, Alanna G Spiteri, Pranav Runwal, Jiaqi Sun, Dana S Hutchinson iD, Yoshiteru Kagawa, Bradley J Turner iD, Cheng Huang, Anup D Shah, Ralf B Schittenhelm, Joseph A Nicolazzo iD

British Journal of Pharmacology · 2026-01 · 183 (2) · 280-295

DOI: 10.1111/bph.70147 ↗

At a glance

Journal article in British Journal of Pharmacology, 2025-09. Written by Yijun Pan and 10 co-authors. Institution: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Major MEDLINE topics: Amyotrophic Lateral Sclerosis, Blood-Brain Barrier, Adenosine Triphosphate, ATP Binding Cassette Transporter, Subfamily B, Member 1. Cited 4 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Health and Medical Research Council, FightMND, Alzheimer's Association.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and purpose Patients with amyotrophic lateral sclerosis (ALS) are prescribed many medications for symptomatic relief. However, how potential alterations to the blood–brain barrier (BBB) affect the brain exposure of drugs in ALS remains under‐investigated. Experimental approach We used high‐dimensional proteomic analysis, cellular metabolism, and mitochondrial functional assays to characterise isolated brain microvascular endothelial cells (BMECs) from wildtype and SOD1 G93A transgenic mice, a mouse model of familial ALS, at a late‐symptomatic age (P115–120), together with a transcardiac brain perfusion technique to assess BBB function in situ . Key results The BBB of the SOD1 G93A transgenic (TG) mice was significantly altered, including a 1.3‐fold decrease in apparent brain microvascular volume, and decreased BBB transport of 3 H‐diazepam (1.4‐fold) and 3 H‐2‐deoxy‐D‐glucose (1.2‐fold). BMEC proteomic analysis revealed multiple changes in TG mice including altered transmembrane activity, metabolism, and mitochondrial function, as revealed by gene set enrichment analysis, alongside altered glucose transporter (Glut1) abundance. These proteomic findings supported the identified increase in mitochondrial basal/ATP‐linked respiration, mitochondrial action potential, ATP production, and intracellular ATP levels in SOD1 G93A mouse BMECs. The BBB transport of 3 H‐digoxin, a specific ATP‐binding cassette efflux P‐glycoprotein (P‐gp) substrate, was reduced by 11.0% in SOD1 G93A mice. This was confirmed by a 46.7% reduction in BMEC uptake of 3 H‐digoxin, an observation that was reversed by resolving the hypermetabolic state of SOD1 G93A BMECs. Conclusion and implications These findings open possible therapeutic avenues that could be exploited to overcome P‐gp‐mediated CNS drug resistance in ALS.

Subjects

MeSH terms (MEDLINE)

Amyotrophic Lateral SclerosisBlood-Brain BarrierAdenosine TriphosphateATP Binding Cassette Transporter, Subfamily B, Member 1AnimalsMice, TransgenicDisease Models, AnimalMiceBiological TransportEndothelial CellsMaleHumansMice, Inbred C57BLCells, CulturedProteomics

Author keywords

P‐glycoproteinamyotrophic lateral sclerosisblood–brain barriermetabolismproteomics

Substances

Adenosine TriphosphateATP Binding Cassette Transporter, Subfamily B, Member 1

Authors and institutions

  • Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Department of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
  • The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.
  • Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.
  • Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

ORCID profiles: Yijun Pan, Dana S Hutchinson, Bradley J Turner, Joseph A Nicolazzo

Funding

  • National Health and Medical Research Council
  • FightMND
  • Alzheimer's Association

Cite

APA

Pan, Y., Spiteri, A. G., Runwal, P., Sun, J., Hutchinson, D. S., Kagawa, Y., Turner, B. J., Huang, C., Shah, A. D., Schittenhelm, R. B., & Nicolazzo, J. A. (2026). Increased ATP production and P‐glycoprotein activity underlie the marked changes in blood–brain barrier transport of drugs in a mouse model of amyotrophic lateral sclerosis. British Journal of Pharmacology, 183(2), 280-295. https://doi.org/10.1111/bph.70147

Vancouver

Pan Y, Spiteri AG, Runwal P, Sun J, Hutchinson DS, Kagawa Y, et al. Increased ATP production and P‐glycoprotein activity underlie the marked changes in blood–brain barrier transport of drugs in a mouse model of amyotrophic lateral sclerosis. British Journal of Pharmacology. 2026;183(2):280-295. doi:10.1111/bph.70147

BibTeX
@article{Pan2026,
  author = {Pan, Yijun and Spiteri, Alanna G and Runwal, Pranav and Sun, Jiaqi and Hutchinson, Dana S and Kagawa, Yoshiteru and Turner, Bradley J and Huang, Cheng and Shah, Anup D and Schittenhelm, Ralf B and Nicolazzo, Joseph A},
  title = {Increased ATP production and P‐glycoprotein activity underlie the marked changes in blood–brain barrier transport of drugs in a mouse model of amyotrophic lateral sclerosis},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {2},
  pages = {280--295},
  doi = {10.1111/bph.70147}
}
Start for free →